Diabetes

Latest News


Advancing Care in Type 2 Diabetes and Obesity: A Coordinated, Guideline-Driven Approach

Understand how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity through a shift of reactive to proactive care that addresses root causes of cardiometabolic disease.

Advancing Care in Type 2 Diabetes and Obesity: A Coordinated, Guideline-Driven Approach

Latest Videos


CME Content


More News

Teenagers with obesity, type 2 diabetes (T2D), or high blood pressure may have a higher risk of experiencing premature vascular aging compared with teens without the conditions, according to a study published in the Journal of the American Heart Association.

African Americans with severe sleep apnea are more likely to have higher blood glucose levels, according to a new study published in the Journal of the American Heart Association. High blood glucose levels increase the risk of developing diabetes, a disease already more prevalent in African Americans.

Recently, it has been shown that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. For this reason, along with increasing prevalence of type 2 diabetes (T2D), effective, patient-centered management of coronary artery disease (CAD) in patients with diabetes is imperative to optimize patient outcomes, the American Heart Association said.

This week, the top managed care news includes a CDC report says diabetes is the condition most linked with coronavirus disease 2019, CMS temporarily suspends rules to give hospitals more capacity during the COVID-19 pandemic, and a late-stage trial for dapagliflozin ends early after showing efficacy for chronic kidney disease.

Researchers found that 1 in 10 patients with diabetes initially hospitalized for treatment of common medical conditions was discharged with intensified diabetes medications, with nearly half unlikely to benefit due to limited life expectancy or already having an optimal blood glucose level.

Michael D. Abramoff, MD, PhD, is the Robert C. Watzke, MD Professor of ophthalmology and visual sciences at the University of Iowa Carver College of Medicine. He is also a professor of electrical and computer engineering and a professor of biomedical engineering at the University of Iowa. Abramoff’s research interests include how autonomous artificial intelligence (AI) can be used to improve the lives of patients, with a focus on autonomous AI-based diagnostic and quantification algorithms for retinal disease. He is the founder and executive chairman of IDx Technologies, which developed IDx-DR, an FDA-authorized autonomous AI diagnostic system for the detection of diabetic retinopathy and macular edema. An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Abramoff regarding the use of AI in the diagnosis of diabetic retinopathy.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo